Latest Intellectual Property News

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

Battery Age Minerals has secured a significant germanium-gallium asset in Utah, marking its strategic entry into the US market and complementing its European portfolio. The move aligns with growing Western efforts to secure critical semiconductor metals.

I Synergy Group Limited has formalised a strategic AI infrastructure agreement with Treasure Global Inc. and launched a partnership with Octagram Investment Limited, signalling early moves into AI-powered digital technologies.

Papyrus Australia has taken a major step towards commercialisation by signing a $4.2 million binding Terms Sheet with TBS Mining Solutions and progressing a high-volume production facility in Vietnam. The company also secured a $250,000 government grant and restructured its leadership to support growth.

Talga Group has made significant strides in Q1 FY2026 with key partnerships in the US and Germany, new patents, and a substantial Swedish government grant to advance its battery anode production.

Dotz Nano has secured its first commercial order for its advanced carbon capture sorbent and raised A$1.2 million to accelerate development of its DotzEarth technology, marking a pivotal step towards commercialization in the growing DAC market.

Identitii Limited has signed six new data sharing agreements with NSW clubs, expanded its BNDRY platform capabilities, and welcomed major shareholder Cameron Beavis to its board, signaling strong momentum ahead.

Altech Batteries has launched immediate sales of sodium nickel chloride batteries through a strategic collaboration with AMPower, while advancing its flagship CERENERGY project in Germany with strong funding and prototype milestones.

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Temas Resources has completed its acquisition of ORF Technologies, gaining full ownership of the patented Regenerative Chloride Leach (RCL) technology that promises significant cost and environmental advantages in critical metals processing.